Current evidence on screening for renal cancer

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

DOI

  • Juliet Usher-Smith, University of Cambridge
  • ,
  • Rebecca K. Simmons
  • ,
  • Sabrina H. Rossi, University of Cambridge
  • ,
  • Grant D. Stewart, University of Cambridge

Renal cell carcinoma (RCC) incidence is increasing worldwide. A high proportion of individuals are asymptomatic at diagnosis, but RCC has a high mortality rate. These facts suggest that RCC meets some of the criteria for screening, and a new analysis shows that screening for RCC could potentially be cost-effective. Targeted screening of high-risk individuals is likely to be the most cost-effective strategy to maximize the benefits and reduce the harms of screening. However, the size of the benefit of earlier initiation of treatment and the overall cost-effectiveness of screening remains uncertain. The optimal screening modality and target population is also unclear, and uncertainties exist regarding the specification and implementation of a screening programme. Before moving to a fully powered trial of screening, future work should focus on the following: developing and validating accurate risk prediction models; developing non-invasive methods of early RCC detection; establishing the feasibility, public acceptability and potential uptake of screening; establishing the prevalence of RCC and stage distribution of RCC detected by screening; and evaluating the potential harms of screening, including the impact on quality of life, overdiagnosis and over-treatment.

OriginalsprogEngelsk
TidsskriftNature Reviews Urology
Vol/bind17
Nummer11
Sider (fra-til)637-642
Antal sider6
ISSN1759-4812
DOI
StatusUdgivet - nov. 2020

Se relationer på Aarhus Universitet Citationsformater

ID: 200434738